Blood samples from mice treated with rapamycin exhibited a clear reduction in GFP+CD19+ CLL-like cells compared with AZD2014 and vehicle treated mice (Fig. 5A & Supplementary Fig. 8). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.